Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018365 | 0.91 | SMN1; SMN2 (0.36) | ALDH1A1GAAMAPK1KMT2ATSHR | |
| SCHEMBL3003770 | 0.90 | F2RL3 (0.35) | KMT2ATSHRSMN1; SMN2F2RL3CHRM5 | |
| SCHEMBL3016779 | 0.89 | TP53 (0.45) | ALDH1A1GAAMAPK1KMT2ATSHR | |
| SCHEMBL3007705 | 0.89 | CHRM5 (0.35) | GAAMAPK1KMT2ASMN1; SMN2CHRM5 | |
| SCHEMBL3015458 | 0.88 | MAPT (0.36) | ALDH1A1GAAMAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL3014619 | 0.88 | CYP3A4 (0.39) | ALDH1A1GAAMAPK1KMT2ATSHR | |
| SCHEMBL3015088 | 0.88 | CHRM5 (0.35) | CHRM5HRH3 | |
| SCHEMBL3020081 | 0.87 | RAB9A (0.38) | ALDH1A1GAAKMT2ASMN1; SMN2F2RL3 | |
| SCHEMBL3016132 | 0.87 | MEN1 (0.39) | ALDH1A1GAAMAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL3017066 | 0.87 | DRD2 (0.35) | ALDH1A1GAAMAPK1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | ALDH1A1 3510/4885GAA 110/4885MAPK1 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.